These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20225915)

  • 1. Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.
    Smith KJ; Raymund M; Nowalk MP; Roberts MS; Zimmerman RK
    Am J Manag Care; 2010 Mar; 16(3):200-6. PubMed ID: 20225915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
    Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
    Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.
    Lin CJ; Zimmerman RK; Smith KJ
    Am J Manag Care; 2013 Jan; 19(1):e30-7. PubMed ID: 23379777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.
    Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ
    J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
    Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK
    Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan.
    Nakamura S; Mikami M; Hayamizu T; Yonemoto N; Moyon C; Gouldson M; Crossan C; Vietri J; Kamei K
    Expert Rev Vaccines; 2024; 23(1):546-560. PubMed ID: 38703180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
    You JH; Wong WC; Ip M; Lee NL; Ho SC
    J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic.
    Rubin JL; McGarry LJ; Klugman KP; Strutton DR; Gilmore KE; Weinstein MC
    BMC Infect Dis; 2010 Jan; 10():14. PubMed ID: 20092638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.
    Caldwell R; Roberts CS; An Z; Chen CI; Wang B
    BMC Infect Dis; 2015 Jul; 15():284. PubMed ID: 26206275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians.
    Dirmesropian S; Wood JG; MacIntyre CR; Beutels P; McIntyre P; Menzies R; Reyes JF; Chen C; Newall AT
    Vaccine; 2017 Aug; 35(34):4307-4314. PubMed ID: 28693751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Am J Prev Med; 2020 Apr; 58(4):487-495. PubMed ID: 32001052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
    Lara C; De Graeve D; Franco F
    Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil.
    Neto JT; de Araujo GT; Gagliardi A; Pinho A; Durand L; Fonseca M
    Hum Vaccin; 2011 Oct; 7(10):1037-47. PubMed ID: 21941088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis.
    Rozenbaum MH; van Hoek AJ; Fleming D; Trotter CL; Miller E; Edmunds WJ
    BMJ; 2012 Oct; 345():e6879. PubMed ID: 23103369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
    Wateska AR; Nowalk MP; Zimmerman RK; Smith KJ; Lin CJ
    BMC Infect Dis; 2018 Jan; 18(1):52. PubMed ID: 29370768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.